Pregunta del mes | Kern Pharma Biologics

Risk and Survival of Patients with Head and Neck Cutaneous Melanoma: National Perspective

0
0 / 5 (0 votos)

Oncology: International Journal of Cancer Research and Treatment
2017, Vol.93, No. 1
DOI: https://doi.org/10.1159/000458530

Al-Qurayshi Z., Hassan M., Srivastav S., Sperry S., Pagedar N., Hamner J., Kandil E.

Objective: Head and neck cutaneous melanoma represents a distinct entity of skin cancer. We aim to examine management and survival of patients with head and neck cutaneous melanoma.

Methods: A retrospective cohort study utilizing the National Cancer Database, 2004-2012.

Results: A total of 20,322 (21.2%) head and neck melanomas and 75,547 (78.8%) melanomas of other sites were included. The median follow-up time of head and neck melanoma was 41.6 months (interquartile range: 22.9-68.2 months). Patients with melanoma of the head and neck were more likely to be ≥65 years old, male, and/or white (p < 0.001 each). Positive…

Seguir leyendo